Blinatumomab Linked to Higher Costs, Hospitalizations for R/R ALL
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
All patients with cardiotoxicity recovered within 2 months.
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
Changes in weight, BMI, and decreased height persist long-term after treatment for AML in pediatric patients.
A leukemia or lymphoma diagnosis was tied to lower vaccine effectiveness.
A retrospective analysis sought to determine the real world outcomes for patients with AML treated with venetoclax and azacitidine or decitabine.
A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.
The approval was based on data from the phase 3 AGILE trial.
Researchers sought to determine whether a reinduction therapy approach using mitoxantrone with clofarabine would be safe and effective for pediatric patients with leukemia.